DK0804237T3 - Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 - Google Patents
Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4Info
- Publication number
- DK0804237T3 DK0804237T3 DK95908741T DK95908741T DK0804237T3 DK 0804237 T3 DK0804237 T3 DK 0804237T3 DK 95908741 T DK95908741 T DK 95908741T DK 95908741 T DK95908741 T DK 95908741T DK 0804237 T3 DK0804237 T3 DK 0804237T3
- Authority
- DK
- Denmark
- Prior art keywords
- humanized antibodies
- adhesion molecule
- leukocyte adhesion
- molecule vla
- vla
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18626994A | 1994-01-25 | 1994-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0804237T3 true DK0804237T3 (da) | 2006-10-16 |
Family
ID=22684288
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06013916.9T DK1759709T3 (da) | 1994-01-25 | 1995-01-25 | Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 |
| DK95908741T DK0804237T3 (da) | 1994-01-25 | 1995-01-25 | Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06013916.9T DK1759709T3 (da) | 1994-01-25 | 1995-01-25 | Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 |
Country Status (21)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
| JP3593343B2 (ja) * | 1993-02-09 | 2004-11-24 | バイオジェン インコーポレイテッド | インシュリン依存型糖尿病の治療 |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| WO1998051345A2 (en) * | 1997-05-09 | 1998-11-19 | The John P. Robarts Research Institute | Method for dislodging infiltrated leukocytes from a tissue |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| CN1236815C (zh) * | 1998-09-14 | 2006-01-18 | 德克萨斯州立大学董事会 | 整联蛋白拮抗剂在制备治疗多发性骨髓瘤和骨髓瘤诱发的骨吸收的药物中的应用 |
| EA006681B1 (ru) * | 1999-04-22 | 2006-02-24 | Байоджен Айдек Ма Инк. | Применение антагонистов взаимодействия vla-4 и альфа-4-бета-7 с соответствующими альфа-4-лигандами для лечения фиброза |
| DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EP2314315B1 (en) | 1999-06-01 | 2015-01-21 | Biogen Idec MA Inc. | A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| DK2140881T3 (da) * | 1999-12-16 | 2013-05-06 | Biogen Idec Inc | Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister |
| DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| AR036330A1 (es) | 2001-04-13 | 2004-09-01 | Biogen Inc | Un anticuerpo anti-vla-1, una composicion que lo incluye, un acido nucleico aislado consistente en una secuencia de codificacion de dicho anticuerpo, un metodo para determinar el nivel de vla-1 en un tejido, celulas del hibridoma de dicho anticuerpo, una computadora que produce una representacion tr |
| DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
| ATE512163T1 (de) * | 2002-02-25 | 2011-06-15 | Elan Pharm Inc | Verabreichung von mitteln zur behandlung von entzündungen |
| EP2270049A3 (en) * | 2002-04-12 | 2011-03-09 | Medimmune, Inc. | Recombinant anti-interleukin-9-antibody |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| TWI323265B (en) * | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| EP2615087A3 (en) | 2003-12-22 | 2013-08-07 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
| AU2005306399B2 (en) * | 2004-11-19 | 2012-02-09 | Biogen Ma Inc. | Treatment for multiple sclerosis |
| CA2629147A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin |
| EP2034830B1 (en) | 2006-05-25 | 2014-09-03 | Biogen Idec MA Inc. | Anti-vla-1 antibody for treating stroke |
| CA2714335A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| AR067011A1 (es) * | 2007-06-14 | 2009-09-30 | Biogen Idec Inc | Formulaciones de anticuerpos |
| US8066917B2 (en) | 2007-12-13 | 2011-11-29 | Tokuyama Corporation | Photochromic curable composition |
| EP2860260A1 (en) | 2008-04-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| AU2010226814B2 (en) | 2009-03-20 | 2013-05-16 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| CN103038257A (zh) | 2010-04-16 | 2013-04-10 | 比奥根艾迪克Ma公司 | 抗vla-4抗体 |
| LT2704742T (lt) | 2011-05-02 | 2017-10-25 | Millennium Pharmaceuticals, Inc. | Anti-alfa4beta7 antikūno kompozicija |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| ES2732243T3 (es) | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
| US20190225694A1 (en) | 2016-06-28 | 2019-07-25 | Zaklady Farmaceutyczne Polpharma Sa | Recombinant production of monoclonal antibodies |
| WO2018091729A2 (en) | 2016-11-21 | 2018-05-24 | Zaklady Farmaceutyczne Polpharma Sa | Aqueous pharmaceutical formulations |
| CN110997714B (zh) * | 2017-02-17 | 2024-05-03 | 赛诺菲 | 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子 |
| US12043845B2 (en) | 2017-06-08 | 2024-07-23 | Polpharma Biologics S.A. | Methods of cell culture |
| US12037398B2 (en) | 2018-06-04 | 2024-07-16 | Biogen Ma Inc. | Anti-VLA-4 antibodies having reduced effector function |
| WO2022162164A1 (en) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| IL95501A (en) * | 1989-09-01 | 1997-04-15 | Hutchinson Fred Cancer Res | Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies |
| DE69309906T2 (de) * | 1992-02-12 | 1997-11-06 | Biogen, Inc., Cambridge, Mass. | Behandlung für entzündungserkrankung des darmes |
| NZ261259A (en) * | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
| AUPP647298A0 (en) | 1998-10-13 | 1998-11-05 | Keystone Retaining Wall Systems, Inc. | Retaining wall block |
-
1995
- 1995-01-25 DE DE1995635133 patent/DE122006000043I1/de active Pending
- 1995-01-25 AT AT95908741T patent/ATE333895T1/de active
- 1995-01-25 HU HU9602019A patent/HU220799B1/hu active Protection Beyond IP Right Term
- 1995-01-25 JP JP51977095A patent/JP4115517B2/ja not_active Expired - Lifetime
- 1995-01-25 CA CA002182013A patent/CA2182013C/en not_active Expired - Lifetime
- 1995-01-25 AU AU16960/95A patent/AU703152B2/en not_active Expired
- 1995-01-25 PL PL95315634A patent/PL181827B1/pl unknown
- 1995-01-25 CN CNB951913549A patent/CN1211123C/zh not_active Expired - Lifetime
- 1995-01-25 EP EP06013916A patent/EP1759709B1/en not_active Expired - Lifetime
- 1995-01-25 PT PT95908741T patent/PT804237E/pt unknown
- 1995-01-25 KR KR1019960703987A patent/KR100367948B1/ko not_active Expired - Lifetime
- 1995-01-25 EP EP95908741A patent/EP0804237B8/en not_active Expired - Lifetime
- 1995-01-25 DE DE69535133T patent/DE69535133T2/de not_active Expired - Lifetime
- 1995-01-25 WO PCT/US1995/001219 patent/WO1995019790A1/en active IP Right Grant
- 1995-01-25 ES ES95908741T patent/ES2270425T3/es not_active Expired - Lifetime
- 1995-01-25 ES ES06013916T patent/ES2424292T3/es not_active Expired - Lifetime
- 1995-01-25 DK DK06013916.9T patent/DK1759709T3/da active
- 1995-01-25 DK DK95908741T patent/DK0804237T3/da active
- 1995-01-25 NZ NZ279730A patent/NZ279730A/en not_active IP Right Cessation
-
1996
- 1996-07-24 FI FI962958A patent/FI117509B/fi active Protection Beyond IP Right Term
- 1996-07-24 NO NO19963097A patent/NO319867B1/no not_active IP Right Cessation
- 1996-07-24 MX MX9602971A patent/MX9602971A/es unknown
-
2005
- 2005-08-05 JP JP2005228930A patent/JP2006045237A/ja not_active Withdrawn
-
2006
- 2006-07-27 FR FR06C0024C patent/FR06C0024I2/fr active Active
- 2006-08-02 LU LU91271C patent/LU91271I2/fr unknown
- 2006-08-02 NL NL300238C patent/NL300238I2/nl unknown
- 2006-08-07 NO NO2006008C patent/NO2006008I2/no unknown
-
2009
- 2009-05-18 JP JP2009120421A patent/JP2009235078A/ja not_active Withdrawn
-
2013
- 2013-02-18 JP JP2013028635A patent/JP5487382B2/ja not_active Expired - Lifetime
- 2013-03-18 JP JP2013054628A patent/JP2013165718A/ja not_active Withdrawn
-
2017
- 2017-08-01 NO NO2017040C patent/NO2017040I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0804237T3 (da) | Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 | |
| NO961151D0 (no) | Antistoffer mot CD40 | |
| ATE347565T1 (de) | Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien | |
| DE69531679D1 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
| RS80704A (en) | ANTI- av?6.ANTIBODIES | |
| ATE218387T1 (de) | Antikörperreinigung | |
| ATE155818T1 (de) | Nicht glycosylierter anti-cd3-igg-antikörper | |
| ATE531812T1 (de) | Humanisierung von nager-antikörpern | |
| DK1414861T3 (da) | Humaniserede antistoffer mod ICAM-1, fremstilling og anvendelse heraf | |
| DE59209129D1 (de) | Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression | |
| IL141158A0 (en) | A humanized immunoglobulin which binds to human von willebrand factor | |
| ATE206621T1 (de) | Il-8 antagonisten zur behandlung von asthma | |
| DE69103214D1 (de) | Verfahren zur Reinigung von Glycin. | |
| DE69527868D1 (de) | Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II) | |
| DE69601154D1 (de) | Zubereitungen für die Behandlung von Hepatitis C |